ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on May 20, 2024. The report discloses a significant regulatory milestone regarding the Company's TAEUS liver device, specifically an in-person pre-submission meeting with the U.S. Food and Drug Administration (FDA).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory events and does not contain financial statements or performance metrics.
Material Changes and Regulatory Updates
- FDA Meeting: The Company held an in-person pre-submission meeting with the FDA on May 16, 2024, to discuss the clinical trial design for the TAEUS liver device.
- Submission Plan: The meeting supports the Company's planned de novo filing with the FDA.
Guidance, Outlook, and Risks
Management provided the following forward-looking timeline for the TAEUS liver device:
- Clinical Studies: Anticipated completion in the fourth quarter of 2024 or the first quarter of 2025.
- De Novo Filing: Anticipated submission to the FDA in the first half of 2025.
Risks and Contingencies: The filing includes a cautionary note regarding forward-looking statements. Actual results may differ materially from expectations due to various factors, and the Company assumes no obligation to update these statements except as required by law.
Key Facts for Investor Verification
- Verify the specific outcomes and feedback received from the FDA pre-submission meeting held on May 16, 2024.
- Monitor the progress of clinical studies to ensure alignment with the Q4 2024/Q1 2025 completion timeline.
- Confirm the status of the de novo filing submission in the first half of 2025.
- Review the attached press release (Exhibit 99.1) for detailed commentary on the clinical trial design discussed with the FDA.